Latest Publications

Share:

EDGAR Next: What Filers Should Know

On September 27, 2024, the SEC adopted new rules, called “EDGAR Next,” to enhance the security of the EDGAR system. Action to comply with EDGAR Next is required of every entity and individual that currently makes EDGAR...more

SEC Expands Confidential Registration Statement Filing Process

The SEC announced that companies can now submit registration statements for confidential review before public filing in connection with most registered offerings. This expansion builds on the confidential filing process that...more

Telehealth Transformation: Innovating Mental Health Care Life Sciences Snapshot – Q1 2025

Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and investment is back on the...more

The Download: A Private Sector Model for Responsible AI in Healthcare & Why Value-Based Care Is Good Business

WHAT WE'RE SEEING - In this Life Sciences & Healthtech edition of The Download, we take on key trends at the intersection of tech and healthcare, continuing the energizing conversation from JPM Healthcare last week. 01 A...more

Life Sciences Snapshot – Q4 2024 – A Quarterly Report on Financing Trends

Since the previous quarter’s Life Sciences Snapshot, robust dealmaking activity in Q3 has launched YTD life sciences VC deal activity to near parity with 2023 figures, firmly positioning 2024 as the year to break the two-year...more

Fifth Circuit Strikes Down Nasdaq Board Diversity Rules

The U.S. Court of Appeals for the Fifth Circuit vacated the SEC’s approval of Nasdaq’s board diversity rules. Consequently, Nasdaq-listed companies are no longer required to satisfy Nasdaq’s “comply or explain” director...more

The Download: Market Outlook with TD Cowen & Is the Death Spiral a Myth?

I'm really excited to be here with you today for two reasons. One, we've never been in the same room together, so it’s awesome to finally be able to do that. But the second reason is that earlier this year, you and I had the...more

SEC Comment Letter Trend: AI-Related Disclosures

SEC officials have declared artificial intelligence (“AI”) “the most transformative technology of our times” while cautioning that “if a public company is using AI, that company has to be honest about the role AI plays in its...more

Best Practices for Preparing Your Company for Exit [Video]

It’s never too early to prepare an exit strategy, whether that exit is through an M&A, IPO or additional private financing. Albert Vanderlaan, Justin Yi and Samir Bakhru discuss the need for good corporate hygiene, process...more

A Conversation with Evercore on the Market Outlook

01 A conversation with Evercore on the market outlook 02 Will there be an alternative path to public? 03 What’s ahead for tech and life sciences IPOs? 04 The Download Quiz: Venture Capital Trends / 01A CONVERSATION WITH...more

Life Sciences Snapshot – Q3 2024 – A Quarterly Report on Financing Trends

This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2024 include: • Life sciences VC deal value reached $10.6 billion in Q2 2024, up more than 30% from Q1, which brings the...more

The Download: Do I need to make money to go public?

01 Do I need to make money to go public?02 A new M&A playbook in the age of AI03 Cyber enforcement forecast post-SolarWinds decision04 Cyber diligence for IPOs with Kroll’s CISO05 The Download Quiz: Venture capital trends...more

Life Sciences Snapshot – Q2 2024 – A Quarterly Report on Financing Trends

This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2024 include: • Life sciences VC deal value in Q1 totaled $7.8 billion, which represents a 22.1% increase in value from Q4...more

Insider Trading Policy Key Terms and Trends

With the compliance deadline for the newly issued Item 408(b) of Regulation S-K approaching for calendar-year-end companies and the increased use by the Department of Justice and the SEC of data analytics in pursuing insider...more

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2024

This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior...more

Recent Considerations for Private Companies

Many private companies have not kept up with recent changes affecting when certain disclosures or reports may be required. That consensus, along with other takeaways, emerged in recent panel discussions at the Society for...more

SEC Final SPAC Rules: Key Takeaways

The Securities and Exchange Commission (the “SEC”) has finalized its long-awaited rules regarding special purpose acquisition companies (“SPAC”). So, what are the key aspects of these rules that SPAC market participants...more

Fifth Circuit Vacates SEC’s Share Repurchase Disclosure Rules

On December 19, 2023, the Fifth Circuit officially vacated the SEC’s share repurchase disclosure rules. As a result of the Court’s decision, companies will not need to comply with the now-vacated share repurchase disclosure...more

Update on the SEC's Share Repurchase Disclosure Rules - What Should Companies Do Now?

On October 31, 2023, the Fifth Circuit ruled in Chamber of Commerce of the USA v. SEC that the SEC violated the Administrative Procedure Act when it adopted enhanced share repurchase disclosure rules. The Court provided the...more

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include: Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2023 include: • Life sciences VC deal value in Q2 2023 totaled $6.7 billion across 384 deals, representing a slight...more

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include: • Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2023

This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include: • Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more

New Disclosure Requirements to Consider for 2022 Fiscal Year End, the 2023 Proxy Season and Beyond

2022 was a busy year in rulemaking for the Securities and Exchange Commission (SEC). As a result, there are many new disclosure requirements for companies to keep top of mind as they work through this year’s annual report,...more

Considerations for Company Insiders When Contemplating Pledging Shares

For many insiders at a newly formed public company, a large portion of their net worth is potentially tied up in holdings of their company’s publicly-traded shares. These insiders often face challenges obtaining liquidity...more

55 Results
 / 
View per page
Page: of 3

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide